Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?

Simply Wall St.04-08

Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock. The share price has had a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625949485?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-08 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625949485","market":"sg","top_or_hot":-1,"title":"Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock. The share price has had a...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-08 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock. The share price has had a...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price","article_id":"2625949485","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625949485","pubTimestamp":1775637306,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock.\nThe share price has had a mixed run, with a 7 day return of an 11.0% decline and a 30 day return of a 4.3% decline, set against a year to date return of a 27.1% decline, a 1 year return of 25.9%, and a 3 year return of 112.0%.\nThese moves sit alongside ongoing attention on Mesoblast's position in the biotech sector and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","MSB":"美莎比信托","BK7501":"新冠治疗股","MSB.AU":"MESOBLAST LTD","BK4006":"钢铁","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Mesoblast(ASX：MSB)在最近股价下跌后是否有价值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB":1.5,"DCF":1,"MSB.AU":1.5},"content_text":"Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock. The share price has had a mixed run, with a 7 day return of an 11.0% decline and a 30 day return of a 4.3% decline, set against a year to date return of a 27.1% decline, a 1 year return of 25.9%, and a 3 year return of 112.0%. These moves sit alongside ongoing attention on Mesoblast's position in the biotech sector and investor focus on its funding, regulatory progress and commercialisation plans. Together, these themes help explain why sentiment around the stock has shifted at different points over recent months. Mesoblast currently has a valuation score of 2 out of 6. Next, you will see how different valuation approaches assess that score, followed by a way of looking at value that can give an even clearer picture by the end of the article.  Mesoblast scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Mesoblast Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those amounts back to today, aiming to express them as a single present value per share. For Mesoblast, the latest twelve month Free Cash Flow is a loss of $60.99 million. Analysts have projected future Free Cash Flow, with one specific data point of $253.24 million in 2028. Simply Wall St then extrapolates further out to build a ten year cash flow path using a 2 Stage Free Cash Flow to Equity model. These projections are all calculated in $ and then discounted back to today. On this basis, the model estimates a DCF fair value of $37.24 per share. Compared with the recent share price around A$2.02, the DCF output suggests Mesoblast is trading at a very large discount, with the intrinsic discount figure indicating the stock is 94.6% undervalued according to this method. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Mesoblast is undervalued by 94.6%. Track this in your watchlist or portfolio, or discover 8 more high quality undervalued stocks. MSB Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Mesoblast. Approach 2: Mesoblast Price vs Sales For companies where earnings are not yet positive or are still volatile, the P/S ratio is often more useful than P/E because it compares the share price to current revenue rather than profit. Investors usually pay a higher or lower multiple of sales depending on what they think about a company’s future growth and risk, so a “normal” or “fair” P/S ratio tends to be higher for businesses with stronger growth expectations and lower perceived risk. Mesoblast currently trades on a P/S ratio of 28.18x. This sits above the Biotechs industry average of 14.25x and also above the peer average of 23.21x, so on simple comparisons the stock is priced at a higher multiple of sales than many peers. Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/S ratio could reasonably be, based on factors such as earnings growth, industry, profit margins, market cap and company specific risks. This Fair Ratio of 5.54x aims to give a more tailored benchmark than a plain industry or peer average because it adjusts for Mesoblast’s own characteristics rather than treating all biotechs as similar. Comparing this 5.54x Fair Ratio to the current 28.18x P/S suggests the shares are trading above that tailored estimate. Result: OVERVALUED ASX:MSB P/S Ratio as at Apr 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 4 top founder-led companies. Upgrade Your Decision Making: Choose your Mesoblast Narrative Earlier it was mentioned that there is an even better way to think about valuation. Narratives let you set out your own story for Mesoblast by linking what you believe about its products, trials and markets to a forecast for revenue, earnings and margins. This then flows through to a Fair Value that can be compared with the current share price. Narratives on Simply Wall St sit inside the Community page and are easy to use, with the platform used by millions of investors and updating those Fair Values automatically when new information such as news or earnings is added. For Mesoblast, one investor might build a more optimistic Narrative around the higher A$4.71 Fair Value scenario, while another might lean toward the more cautious A$3.11 view. By setting these out side by side you can see how different assumptions about future earnings, margins and required P/E multiples can lead to very different Fair Values and potential investment decisions. Do you think there's more to the story for Mesoblast? Head over to our Community to see what others are saying! ASX:MSB 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625949485","isCrawlerRequest":true}